Skip to main content
Clinical Trials/NCT02081989
NCT02081989WithdrawnPhase 4

Effect of Renal Sympathetic Denervation on Glycemic Status Independent of Blood Pressure-lowering.

Monash University1 site in 1 countryStarted: November 1, 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Locations
1
Primary Endpoint
Glycemic control

Study Overview

Brief Summary

Renal denervation (the use of radio waves to oblate the renal artery) has been shown to be an effective treatment for high blood pressure. It is currently being tested in heart failure patients and we would now like to look it its effects on diabetes.

We therefore plan to enrol 20 participants with type II diabetes into this study. Half will undergo renal denervation in addition to their standard care and the other half will act as controls and only receive standard care. Treatment allocation will be randomly assigned.

All participants will undergo screening (including a physical exam, blood tests, ultrasounds and a muscle biopsy). All patients will have follow up tests (including physical exams and blood tests) 1, 3 and 6 months later.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Over 18 years
  • •Able and willing to provide informed consent
  • •Patients with established type II diabetes mellitus (HbA1C>7%, diet or oral hypoglycaemic agents)
  • •Clinical stable as demonstrated by no change in background anti-diabetic medication in the last 30 days.
  • •Anticipated that patients are able to maintain a stable dose of medication for the duration of the study

Exclusion Criteria

  • •Renal arterial anatomy ineligible for RDN: main renal arteries <4 mm in diameter or <20 mm in treatable length; multiple renal arteries where main renal artery is estimated to supply <75% of the kidney; haemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, in the investigator's opinion, would interfere with safe cannulation of the renal artery or require surgical repair or interventional dilation
  • •History of prior renal artery intervention including balloon angioplasty, stenting or previous renal denervation.
  • •Single functioning kidney
  • •Need for insulin (interferes with euglycemic clamp testing) or GLP-I analogues
  • •eGFR <30 ml/min (MDRD formula)
  • •Any medical condition which, in the investigators opinion, may adversely affect the participants safety in the trial

Arms & Interventions

Denervation

Experimental

Renal denervation

Intervention: Renal denervation (Procedure)

No intervention

No Intervention

Control group - no intervention

Outcomes

Primary Outcomes

Glycemic control

Time Frame: 6 months

Change in glycemic control at 6 months.

glucose uptake into peripheral skeletal muscle

Time Frame: 6 months

To assess glucose uptake into peripheral skeletal muscle

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ingrid Hopper

Senior Lecturer

Monash University

Study Sites (1)

Loading locations...

Similar Trials